{Reference Type}: Meta-Analysis
{Title}: Polymorphisms in FSHR modulating susceptibility to polycystic ovary syndrome: an updated meta-analysis.
{Author}: Kaur M;Singh S;Kaur A;
{Journal}: J Ovarian Res
{Volume}: 16
{Issue}: 1
{Year}: 2023 Sep 1
{Factor}: 5.506
{DOI}: 10.1186/s13048-023-01238-7
{Abstract}: <B>BACKGROUND: </B>Two polymorphisms, rs6165 and rs6166 located in the intracellular domain of FSHR has been reported to affect folliculogenesis, steroidogenesis and oocyte maturation. Several studies have highlighted the role of FSHR polymorphisms in PCOS but the findings are conflicting. A meta-analysis was carried out to decipher the emerging perspectives.<BR><B>METHODS: </B>A comprehensive literature search was made using PubMed, PCOSkb, and Google Scholar. New Ottawa Scale has been utilized to evaluate the quality of each article. To evaluate the strength of association under different genetic models of rs6165 and rs6166 polymorphisms, odds ratio with a 95% confidence interval (CI) was calculated.<BR><B>RESULTS: </B>A total of 20 articles were selected for the present study. In pooled analysis and after the stratification by ethnicity, polymorphism rs6165 remains unrelated to the onset of PCOS. Besides, rs6166 exhibits significant protection in the Indian population under recessive, additive, and allele models (OR = 0.7, CI: 0.54-0.9, p = 0.006, OR = 0.65, CI: 0.48-0.89, p = 0.006, OR = 0.82, CI: 0.7-0.95, p = 0.01, respectively) and low to moderate risk in the Caucasian population under allele model (OR = 1.17, CI: 1.04-1.32, p = 0.01).<BR><B>CONCLUSIONS: </B>This meta-analysis suggests that GG genotype of rs6166 provides protection against PCOS, in a population-specific manner.